CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (214)	6/8/1999 10:01:00 PM
From: Bob L	Read Replies (1) of 666

Upon reflection, a few things in the release begin to stand out for me. First, there is the large number of followup patients. It has been less than 18 months since the enrollment for phase III ended, with 60 patients enrolled. It was just last October that they announced the expanded access program, which according to the press release was supposed to "build gradually." So now they have data on 432 patients? This apparently rapid increase in patient numbers would imply that not very many of them can have been free of progression for very long, since it can't be very long since they began treatment. The other thing that stands out is the high incidence of HAMA in previously untreated patients. It is a small sample of 35 patients, but still 54% is a much higher number than I have seen mentioned before.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next